The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
From the Guest EditorFull Access

Neuroscience-Informed Therapies in Psychiatry

I had the pleasure of guest-editing this issue of Focus on neuroscience-informed therapies. Neuroscience has progressed in leaps and bounds in the past few decades. Much of what we now understand about brain and behavior, thanks to advances on many fronts, can be useful to clinicians. However, when surveyed, most clinicians do not feel adequately prepared to access and use this information. Why might that be the case? Neuroscience is a vast and rapidly moving field, and its language can be alien to clinicians. Moreover, the complexity of the brain and of psychiatric disorders is such that no simple explanations of pathophysiology and treatments are readily available. Training psychiatrists who can read and assess relevant neuroscience literature and put it to use in their clinical reasoning as well as in their communication with patients constitutes a major challenge. One extreme has been to define relevant neuroscience in a very limited way, for example, focusing on the effects of drugs on neurotransmitter systems. Another extreme has been to teach basic science—sometimes without using adult learning principles—that has not been vetted for clinical relevance. The former approach misses much of what is relevant to psychiatrists, and the latter confirms their sense that neuroscience is not for them. See the Ask the Expert column in this issue (1).

A similar challenge presented itself when deciding which treatments to include in this issue. The title “Neuroscience-Informed Treatments” may seem to restrict itself to novel drugs that have emerged from a neuroscience-based understanding of the pathophysiology of psychiatric disorders. Taking this approach alone would limit the scope of this issue to experimental treatments in early phases of Food and Drug Administration approval, which may or may not pan out. More important, such an approach embodies a dichotomous view of psychiatric disorders that separates brain and mind and undermines a neuroscientific basis for the efficacy of psychosocial treatments. If, in contrast, we consider the brain–mind connection as inseparable— “thinking matter,” as it were—then all effective psychiatric treatments are neuroscience based. Several of the contributions in this issue take this approach to help clinicians use clinical neuroscience to inform their interactions and communication with patients (2, 3). The media is full of news stories, podcasts, postings, and commentaries about the brain and human behavior. Patients often ask about the relevance of all this to their own suffering and treatment. The Communication Commentary in this issue is an example of how to address such questions (4).

The treatments highlighted in this issue are practical treatments, some of which have been used in psychiatry for some time and are now better understood from the neuroscience perspective. See the piece on therapeutic uses of seizures, for instance (5). Others are newer treatments, with immediate clinical relevance for particular disorders (6, 7). Finally, and perhaps least familiar to clinicians, is a review informing us about transcranial direct current stimulation (8).

I hope you find the contents of this issue to be clinically relevant and intellectually stimulating. Most of all, I hope the information contained in this issue of Focus will inspire you to use a clinical neuroscience perspective in your practice.

Dr. Akil is Vice Chair for Education at the Department of Psychiatry, Medstar Georgetown University Hospital, Washington, D.C.
Send correspondence to Dr. Akil ().
References

1 Travis MJ: Neuroscience and the future of psychiatry. Focus 2019; 17:30–31Google Scholar

2 Cooper JJ, Korb AS, Akil M: Bringing neuroscience to the bedside. Focus 2019; 17:2–7Google Scholar

3 Thurin K, Aftab ZN, Cooper JJ: How neuroscience is informing treatments: ethical issues. Focus 2019; 17:35–40Google Scholar

4 Stubbe D: Media talks: communicating the neuroscience underpinnings of popular media stories. Focus 2019; 17:32–34Google Scholar

5 Coffey MJ, Cooper JJ: Therapeutic uses of seizures in neuropsychiatry. Focus 2019; 17:13–17Google Scholar

6 Park LT, Falodun TB, Zarate CA Jr: Ketamine for treatment-resistant mood disorders. Focus 2019; 17:8–12Google Scholar

7 McClintock SM, Kallioniemi E, Martin DM, et al.: A critical review and synthesis of clinical and neurocognitive effects of noninvasive neuromodulation antidepressant therapies. Focus 2019; 17:18–29Google Scholar

8 Zandvakili A, Berlow Y, Carpenter LL, et al.: Transcranial direct current stimulation in psychiatry: what psychiatrists need to know. Focus 2019; 17:44–49Google Scholar